Navigation Links
Etanercept Challenges Cortisone as Treatment for Sciatica
Date:11/7/2013

Los Angeles, California (PRWEB) November 07, 2013

A new randomized clinical trial (RCT) published in the November 1, 2013 issue of the journal Spine (1) provides new evidence for the efficacy of etanercept used off-label for relief of persistent sciatica associated with lumbar disc herniation, a common health problem with significant unmet medical need. Etanercept belongs to the class of potent anti-inflammatory drugs known as TNF inhibitors.

The new etanercept study follows a 2012 comparative effectiveness trial of epidural etanercept versus an epidural steroid injection that found etanercept to be superior to the epidural steroid(cortisone) injection(2).

The new Spine study joins three previous RCTs as the fourth RCT supporting the efficacy of etanercept for treating disc-related pain(1-4). The clinical evidence of the effectiveness of etanercept for this indication has been accumulating for more than a decade(1-9). Increasing basic science and clinical evidence supports the scientific rationale of TNF inhibition for neuroinflammation(10-19).

The first account of the favorable clinical effect of etanercept for sciatica, and the invention of epidural administration of etanercept for this indication, was published in 2001, authored by Edward Tobinick, M.D., the founder of the Institute of Neurological Recovery(INR)(20). Dr. Tobinick and his colleagues have written multiple peer-reviewed articles documenting the clinical effects of perispinal etanercept used at the INR off-label for sciatica, cervical radiculopathy, intractable low back pain and related symptoms associated with lumbar disc herniation(5-9, 21). Perispinal administration of etanercept is a patented invention of Dr. Tobinick(21). Please note that results can vary, not all patients respond, etanercept may have adverse effects and is off-label for neurological indications.

Etanercept holds great promise for the large patient population with intractable spinal pain for which existing medical treatment options have not provided adequate pain relief.

References

1. Freeman, B.J., et al., Randomized, Double-blind, Placebo-Controlled, Trial of Transforaminal Epidural Etanercept for the Treatment of Symptomatic Lumbar Disc Herniation. Spine (Phila Pa 1976), 2013. 38(23): p. 1986-94.
2. Ohtori, S., et al., Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study. Spine (Phila Pa 1976), 2012. 37(6): p. 439-44.
3. Sainoh, T., et al., Intradiscal Administration of Tumor Necrosis Factor-Alpha Inhibitor, Etanercept, Clinically Improves Intractable Discogenic Low Back Pain: A Prospective Randomized Study, in International Society for the Study of the Lumbar Spine 40th Annual Meeting. 2013: Scottsdale, Arizona.
4. Cohen, S.P., et al., Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. Anesthesiology, 2009. 110(5): p. 1116-26.
5. Tobinick, E.L., Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults. Clinical Therapeutics, 2003. 25(4): p. 1211-8.
6. Tobinick, E.L. and S. Britschgi-Davoodifar, Perispinal TNF-alpha inhibition for discogenic pain. Swiss Med Wkly, 2003. 133(11-12): p. 170-7.
7. Tobinick, E. and S. Davoodifar, Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr Med Res Opin, 2004. 20(7): p. 1075-85.
8. Tobinick, E., Perispinal etanercept for neuroinflammatory disorders. Drug Discov Today, 2009. 14(3-4): p. 168-77.
9. Tobinick, E., Perispinal etanercept: a new therapeutic paradigm in neurology. Expert Review of Neurotherapeutics, 2010. 10(6): p. 985-1002.
10. Kato, K., et al., Distribution and tumor necrosis factor-alpha isoform binding specificity of locally administered etanercept into injured and uninjured rat sciatic nerve. Neuroscience, 2009. 160(2): p. 492-500.
11. Chio, C.C., et al., Therapeutic evaluation of etanercept in a model of traumatic brain injury. J Neurochem, 2010. 115(4): p. 921-9.
12. Clark, I.A., L.M. Alleva, and B. Vissel, The roles of TNF in brain dysfunction and disease. Pharmacol Ther, 2010. 128(3): p. 519-48.
13. Watanabe, K., et al., Etanercept attenuates pain-related behavior following compression of the dorsal root ganglion in the rat. Eur Spine J, 2011. 20(11): p. 1877-84.
14. Shen, C.H., et al., Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats. Anesth Analg, 2011. 112(2): p. 454-9.
15. Tobinick, E., et al., Selective TNF Inhibition for Chronic Stroke and Traumatic Brain Injury : An Observational Study Involving 629 Consecutive Patients Treated with Perispinal Etanercept. CNS Drugs, 2012. 26(12): p. 1051-70.
16. Lei, B., et al., Tumor necrosis factor alpha antagonism improves neurological recovery in murine intracerebral hemorrhage. J Neuroinflammation, 2013. 10(1): p. 103.
17. King, M.D., C.H. Alleyne, Jr., and K.M. Dhandapani, TNF-alpha receptor antagonist, R-7050, improves neurological outcomes following intracerebral hemorrhage in mice. Neurosci Lett, 2013. 542: p. 92-6.
18. Iwatsuki, K., et al., Targeting anti-inflammatory treatment can ameliorate injury-induced neuropathic pain. PLoS One, 2013. 8(2): p. e57721.
19. Boivin, N., et al., The combination of valacyclovir with an anti-TNF alpha antibody [etanercept] increases survival rate compared to antiviral therapy alone in a murine model of herpes simplex virus encephalitis. Antiviral Research, 2013. in press, http://dx.doi.org/10.1016/j.antiviral.2013.10.007.
20. U.S. patent 6,419,944, and additional applicable U.S. patents, Edward Tobinick M.D., inventor, assigned to TACT IP, LLC.
21. Applicable patents, all assigned to TACT IP LLC and licensed to the INR include 6,419,944; 6,982,089 and other issued and pending U.S. patents.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11305858.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Enbrel® (etanercept) Patent Issued
2. Coherus maakt bekend dat CHS-0214 (Proposed Etanercept Biosimilar) het primaire eindpunt in belangrijk farmacokinetisch klinisch onderzoek heeft bereikt
3. Foundation of UMDNJ Receives Grand Challenges Tuberculosis Biomarkers Grant
4. Phigenics Research Challenges Accuracy Of Conventional Legionella Testing Protocol
5. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
6. Functional Circulation LLC Receives Grand Challenges Explorations Grant for Groundbreaking Research in Global Health and Development
7. Biodetection 2012 Conference Brings Together Leading Organizations from Around the World to Address Challenges & Technology Advances in Detection and Identification of Biological Threats in Washington, DC from June 28-29, 2012
8. Healthcare Cloud Computing (Clinical, EMR, SaaS, Private, Public, Hybrid) Market - Global Trends, Challenges, Opportunities & Forecasts (2012 - 2017)
9. Conference Challenges Left-brain, Right-brain Dichotomy
10. Global water sustainability flows through natural and human challenges
11. Bayer Bee Care Center Helps Solve Bee Health’s Toughest Challenges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)...   BioInformant announces the February 2016 release ... Opportunities, Tools, and Technologies – Market Size, Segments, Trends, ... The first and only market ... BioInformant has more than a decade of historical information ... stem cell type. This powerful 175 page global strategic ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... cell treatment clinic in Quito, Ecuador. The new facility will provide advanced protocols ... patients from around the world. , The new GSCG clinic is headed ...
(Date:2/10/2016)... Feb. 10, 2016  The Maryland House of Delegates ... announced that University of Maryland School of Medicine Dean ... University of Maryland Medical System President and CEO ... Medallion," the highest honor given to the public by ... Dean Reece and Mr. Chrencik for their ...
(Date:2/10/2016)... New York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it ... and develop new vaccines and immunotherapies for infectious diseases and cancer. ...
Breaking Biology Technology:
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first ... (AHA) announced plans to develop a first of its ... power of IBM Watson. In the first application of ... IBM (NYSE: IBM ), and Welltok will create ... health assessments with cognitive analytics, delivered on Welltok,s health ...
(Date:1/25/2016)... 25, 2016  Glencoe Software, the world-leading supplier of ... industries, will provide the data management solution OMERO Plus ... Photo - ... Phenotypic analysis measures the characteristics and ... comparisons between states such as health and disease, the ...
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):